These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 12899529

  • 1. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.
    Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
    [Abstract] [Full Text] [Related]

  • 2. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 4. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 5. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3370-5. PubMed ID: 9699668
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
    Haq M, Kremer R, Goltzman D, Rabbani SA.
    J Clin Invest; 1993 Jun 01; 91(6):2416-22. PubMed ID: 8514854
    [Abstract] [Full Text] [Related]

  • 11. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Jun 01; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 12. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
    Love-Schimenti CD, Gibson DF, Ratnam AV, Bikle DD.
    Cancer Res; 1996 Jun 15; 56(12):2789-94. PubMed ID: 8665515
    [Abstract] [Full Text] [Related]

  • 13. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 15; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

  • 14. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH, Zhao XY, Holloway L, Feldman D.
    Endocrinology; 1999 May 15; 140(5):2071-6. PubMed ID: 10218956
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression.
    Sasaki H, Harada H, Handa Y, Morino H, Suzawa M, Shimpo E, Katsumata T, Masuhiro Y, Matsuda K, Ebihara K.
    Biochemistry; 1995 Jan 10; 34(1):370-7. PubMed ID: 7819220
    [Abstract] [Full Text] [Related]

  • 16. Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1,25-dihydroxyvitamin D3.
    Chen TC, Holick MF.
    Br J Dermatol; 2000 Jul 10; 143(1):72-8. PubMed ID: 10886138
    [Abstract] [Full Text] [Related]

  • 17. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
    Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP.
    Oncogene; 2000 Oct 19; 19(44):5091-7. PubMed ID: 11042697
    [Abstract] [Full Text] [Related]

  • 18. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ.
    Recent Results Cancer Res; 2003 Oct 19; 164():83-98. PubMed ID: 12899515
    [Abstract] [Full Text] [Related]

  • 19. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
    Yu J, Papavasiliou V, Rhim J, Goltzman D, Kremer R.
    Anticancer Drugs; 1995 Feb 19; 6(1):101-8. PubMed ID: 7756673
    [Abstract] [Full Text] [Related]

  • 20. 1alpha,25-Dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2.
    Akhter J, Lu Y, Finlay I, Pourgholami MH, Morris DL.
    ANZ J Surg; 2001 Jul 19; 71(7):414-7. PubMed ID: 11450917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.